Vogt_2022_Pharmacol.Biochem.Behav__173357

The present study evaluated the protective effect of 1-(7-chloroquinolin-4-yl)-5-methyl-N-phenyl-1H-1,2,3-triazole-4-carboxamide (QTCA-1) on seizure severity, oxidative stress, and memory disorder in a pentylenetetrazole (PTZ)-kindling model in mice. Male Swiss mice were treated with QTCA-1 (10 mg/kg, intragastrically (i.g.)) or phenobarbital (PHEN) (10 mg/kg; i.g.), 30 min before the injection of PTZ (35 mg/kg, intraperitoneally (i.p.)). Treatments with QCTA-1 or PHEN and PTZ were performed once every 48 h (on the 1st, 3rd, 5th, 7th, 9th and 11th days). After each PTZ injection, the animals were observed for 30 min to assess the stage of seizure intensity. Behavioral parameters were evaluated from the 12th day until the 16th day of the experimental protocol. On the 16th day, mice were euthanized, and the cerebral cortex and hippocampus of mice were removed to determine the thiobarbituric acid reactive species (TBARS) and reactive species (RS) levels, and superoxide dismutase (SOD), Na(+)/K(+)-ATPase and acetylcholinesterase (AChE) activities. Our results demonstrated that QTCA-1 significantly decreased the seizure stage score in PTZ-kindled mice. QCTA-1 protected against memory impairment induced by PTZ. QTCA-1 normalized oxidative stress and Na(+)/K(+)-ATPase activity in the cerebral structures of PTZ-kindled mice. The effect of QTCA-1 treatment was similar to the positive control used in this study (PHEN). AChE activity did not change in the cerebral structures in PTZ- kindling mice. In conclusion, QCTA-1 may be a promising tool for the treatment of epileptogenesis and epilepsy-associated comorbidity (memory impairment). QCTA-1 to prevent these alterations may involve the reduction of oxidative stress and normalization of Na(+)/K(+)-ATPase activity.